Home Uncategorized Page 2

Uncategorized

Latest

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational...

atai Life Sciences to Participate in Upcoming June Investor Conferences

atai Life Sciences Announces First Subject Dosed in the Phase 1...

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial...

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...

atai Life Sciences to Participate in Upcoming May Investor Conference

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late...

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Expanding ketamine’s horizons for rare neurological disorders

123...13 Page 2 of 13

EDITOR PICKS

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.